Impact of Decentralized Clinical Trial Methodologies on Alzheimer’s research

Abstract

AbstractBackgroundThe Decentralized Trials and Research Alliance represents over 120 organizational members including regulatory authorities, biopharmaceutical companies, technology companies, patient advocates, clinical trial sites, and service companies. Four priority areas have been identified to accelerate the adoption of decentralized methodologies where appropriate in clinical research. Within these four priority areas, 12 initiatives were launched.MethodThe more than 120 organization members took part in a formal process to identify priority areas and initiatives that would drive these priorities. Leaders and group members were assigned to these initiatives and clear outputs. For this project we looked at the relevant initiatives that would specifically be relevant to Alzheimer’s disease clinical research and improve the conduct of these trials in areas such as recruitment, patient focus, and diversity.ResultThis presentation will discuss how these initiatives that will have an impact on improving the efficiency and success of research in Alzheimer’s disease.ConclusionAlzheimer’s disease research faces many challenges that include attracting enough clinical trial participants, improving access in an equitable way, including to patients not geographically near clinical trial centers. Decentralized research methodologies can assist clinical trial sponsors and clinical research sites improve on these and many other aspects of clinical research.